Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.75 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871979 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL19549008 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL18922786 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL19549010 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL3694684 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL19565572 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL7996253 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL20980004 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL18576030 | 0.94 | VDR (0.73) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL31504641 | 0.94 | VDR (0.76) | VDRUSP2CYP2C9HIF1AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766921-B2 | Process and intermediates for the 6,7-alpha-epoxidation of steroid 4,6-dienes | NZP UK Limited (GB) | 2020-09-08 | — | — | US | disclosed |
| US-10597423-B2 | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal FXR modulators | NZP UK Limited (GB) | 2020-03-24 | — | — | US | disclosed |
| EP-3221334-B1 | 6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NZP UK LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-20190309012-A1 | Process and Intermediates for the 6,7-Alpha-Epoxidation of Steroid 4,6-Dienes | NZP UK Limited (GB) | 2019-10-10 | — | — | US | disclosed |
| EP-3221331-B1 | 6-ALKYL-7-HYDROXY-4-EN-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NZP UK LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-3221333-B1 | 6.ALPHA.-ALKYL-3,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NZP UK LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-10301350-B2 | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal FXR modulators | NZP UK Limited (GB) | 2019-05-28 | — | — | US | disclosed |
| EP-3221332-B1 | 5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NZP UK LTD (GB) | 2019-04-24 | — | — | EP | disclosed |
| US-20190077827-A1 | 6.Alpha.-Alkyl-6,7-Dione Steroids as Intermediates for the Production of Steroidal FXR Modulators | NZP UK Limited (GB) | 2019-03-14 | — | — | US | disclosed |
| WO-2016079519-A9 | 6.ALPHA.-ALKYL-3,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NZP UK Limited (GB) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017199036-A1 | PROCESS AND INTERMEDIATES FOR THE 6,7-ALPHA-EPOXIDATION OF STEROID 4,6-DIENES | NZP UK Limited (GB) | 2017-11-23 | — | — | WO | disclosed |
| US-20170327528-A1 | 6-ALKYL-7-HYDROXY-4-EN-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR | NZP UK Limited (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170327531-A1 | 6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LTD (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170320907-A1 | 5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LTD (GB) | 2017-11-09 | — | — | US | disclosed |
| WO-2016079518-A1 | 5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079520-A1 | 6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079519-A1 | 6.ALPHA.-ALKYL-3,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079517-A1 | 6-ALKYL-7-HYDROXY-4-EN-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320907-A1 | 5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NR1H4, CYP7A1, GPBAR1 | VDR 108/4885USP2 4557/4885CYP2C9 151/4885 |
| US-20190309012-A1 | Process and Intermediates for the 6,7-Alpha-Epoxidation of Steroid 4,6-Dienes | CYP7A1, CYP11B2, CYP11B1 | VDR 816/4885USP2 3601/4885CYP2C9 128/4885 |
| US-20170327531-A1 | 6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NR1H4, CYP7A1, CYP7B1 | VDR 94/4885USP2 4572/4885CYP2C9 182/4885 |
| US-10597423-B2 | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal FXR modulators | NR1H4, GPBAR1, FXR1 | VDR 176/4885USP2 4428/4885CYP2C9 237/4885 |
| US-10766921-B2 | Process and intermediates for the 6,7-alpha-epoxidation of steroid 4,6-dienes | CYP7A1, CYP11B2, CYP11B1 | VDR 816/4885USP2 3601/4885CYP2C9 128/4885 |
| US-20170327528-A1 | 6-ALKYL-7-HYDROXY-4-EN-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR | NR1H4, CYP7A1, CYP7B1 | VDR 97/4885USP2 4642/4885CYP2C9 145/4885 |
| US-10301350-B2 | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal FXR modulators | NR1H4, NR1H3, NR1H2 | VDR 213/4885USP2 3670/4885CYP2C9 414/4885 |
| US-20190077827-A1 | 6.Alpha.-Alkyl-6,7-Dione Steroids as Intermediates for the Production of Steroidal FXR Modulators | NR1H4, CYP7A1, CYP7B1 | VDR 94/4885USP2 4572/4885CYP2C9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.